BioNTech SE
22UA.F
Get informed when a big investor buys or sells
+ FollowMarket Cap$24.36B
Close$
$41.26
51.1% downside
Current Fair Value
51.1% downsideOvervalued by 51.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $24.36 Billion |
|---|---|
| Enterprise Value | $15.68 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.52 |
| Beta | 1.28 |
| Outstanding Shares | 253,332,000 |
Return
| Return on Equity | -9.61% |
|---|---|
| Return on Assets | -8.39% |
| Return on Invested Capital | -9.18% |
Valuation & Multiples
| P/E Ratio | -12.51 |
|---|---|
| PEG | -10.8 |
| Price to Sales | 8.45 |
| Price to Book Ratio | 1.21 |
| Enterprise Value to Revenue | 5.93 |
| Enterprise Value to EBIT | -9.29 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-2.10
Average shareholder expectationRevenue Estimate
$157.77 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$0.75
Average shareholder expectationRevenue Estimate
$1.06 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BioNTech SE
7,807 employees
CEO: Ugur Sahin BioNTech SE is a biotechnology firm dedicated to the research, development, and marketing of immunotherapies for oncology and a spectrum of infectious diseases. Its diverse product pipeline features several FixVac candidates, including B...